Paul Choi
Stock Analyst at Goldman Sachs
(3.42)
# 902
Out of 4,784 analysts
98
Total ratings
51.56%
Success rate
3.01%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $18 → $12 | $6.60 | +81.82% | 8 | Mar 10, 2025 | |
| ASND Ascendis Pharma | Maintains: Buy | $200 → $225 | $154.68 | +45.46% | 4 | Feb 13, 2025 | |
| RGNX REGENXBIO | Downgrades: Neutral | $38 → $14 | $7.83 | +78.80% | 2 | Feb 11, 2025 | |
| DVAX Dynavax Technologies | Downgrades: Sell | $15 → $12 | $13.68 | -12.28% | 3 | Feb 11, 2025 | |
| LNTH Lantheus Holdings | Initiates: Buy | $143 | $96.16 | +48.71% | 1 | Dec 18, 2024 | |
| ESPR Esperion Therapeutics | Reinstates: Neutral | $4 | $1.50 | +166.67% | 8 | Dec 18, 2024 | |
| PTCT PTC Therapeutics | Maintains: Sell | $32 → $42 | $54.24 | -22.57% | 7 | Dec 4, 2024 | |
| CYTK Cytokinetics | Downgrades: Neutral | $85 → $60 | $43.19 | +38.92% | 2 | Aug 13, 2024 | |
| HCM HUTCHMED (China) | Maintains: Neutral | $17 → $19 | $15.25 | +24.59% | 6 | Aug 1, 2024 | |
| GOSS Gossamer Bio | Maintains: Buy | $8 | $1.17 | +583.76% | 4 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $7.59 | +822.27% | 1 | Feb 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $11 → $18 | $11.20 | +60.71% | 2 | Jul 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $32 | $23.09 | +38.59% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $28 | $6.70 | +317.91% | 7 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $1.5 → $1 | $0.44 | +127.17% | 7 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $50 | $35.11 | +42.41% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $3.52 | +439.77% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $16 → $2 | $0.31 | +537.35% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $34.26 | +75.13% | 1 | Dec 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.11 | +2,152.25% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $4 | $0.23 | +1,638.37% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $27.65 | +514.83% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $3.14 | +154.78% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $33 | $28.98 | +13.87% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $112 | $47.41 | +136.24% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $113.16 | +19.30% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $18 → $20 | $0.74 | +2,608.93% | 2 | Mar 30, 2020 |
Phathom Pharmaceuticals
Mar 10, 2025
Maintains: Neutral
Price Target: $18 → $12
Current: $6.60
Upside: +81.82%
Ascendis Pharma
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $154.68
Upside: +45.46%
REGENXBIO
Feb 11, 2025
Downgrades: Neutral
Price Target: $38 → $14
Current: $7.83
Upside: +78.80%
Dynavax Technologies
Feb 11, 2025
Downgrades: Sell
Price Target: $15 → $12
Current: $13.68
Upside: -12.28%
Lantheus Holdings
Dec 18, 2024
Initiates: Buy
Price Target: $143
Current: $96.16
Upside: +48.71%
Esperion Therapeutics
Dec 18, 2024
Reinstates: Neutral
Price Target: $4
Current: $1.50
Upside: +166.67%
PTC Therapeutics
Dec 4, 2024
Maintains: Sell
Price Target: $32 → $42
Current: $54.24
Upside: -22.57%
Cytokinetics
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $43.19
Upside: +38.92%
HUTCHMED (China)
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $15.25
Upside: +24.59%
Gossamer Bio
Jun 17, 2024
Maintains: Buy
Price Target: $8
Current: $1.17
Upside: +583.76%
Feb 1, 2024
Initiates: Buy
Price Target: $70
Current: $7.59
Upside: +822.27%
Jul 31, 2023
Maintains: Neutral
Price Target: $11 → $18
Current: $11.20
Upside: +60.71%
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $23.09
Upside: +38.59%
Jul 21, 2023
Maintains: Buy
Price Target: $51 → $28
Current: $6.70
Upside: +317.91%
Jul 20, 2023
Maintains: Sell
Price Target: $1.5 → $1
Current: $0.44
Upside: +127.17%
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $35.11
Upside: +42.41%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $3.52
Upside: +439.77%
Jun 27, 2023
Maintains: Sell
Price Target: $16 → $2
Current: $0.31
Upside: +537.35%
Dec 14, 2022
Initiates: Buy
Price Target: $60
Current: $34.26
Upside: +75.13%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.11
Upside: +2,152.25%
May 24, 2022
Maintains: Neutral
Price Target: $10 → $4
Current: $0.23
Upside: +1,638.37%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $27.65
Upside: +514.83%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $3.14
Upside: +154.78%
Mar 22, 2021
Assumes: Buy
Price Target: $33
Current: $28.98
Upside: +13.87%
Mar 22, 2021
Assumes: Buy
Price Target: $112
Current: $47.41
Upside: +136.24%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $113.16
Upside: +19.30%
Mar 30, 2020
Upgrades: Neutral
Price Target: $18 → $20
Current: $0.74
Upside: +2,608.93%